REVIEW OF THE ONCOLOGICAL UROLOGY PROCEEDINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2018 ANNUAL MEETING
Open Access
- 30 September 2018
- journal article
- research article
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 14 (3) , 143-148-148
Abstract
The 54th American Society of Clinical Oncology (ASCO) Annual Meeting took place between 1st and 5th June in Chicago (USA) united more than 40,700 professionals of various fields. Oncological urology topics account for a considerable proportion of the Annual Meeting proceedings. In this article, a review of the most significant reports on cancer urology from the ASCO 2018 Annual Meeting is presented.Keywords
This publication has 9 references indexed in Scilit:
- Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 studyAnnals of Oncology, 2018
- Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet Oncology, 2018
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaNature Medicine, 2018
- Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancerOncotarget, 2018
- Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.Journal of Clinical Oncology, 2018
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThe Lancet, 2018
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaNew England Journal of Medicine, 2017
- Prognostic Genetic Signatures in Upper Tract Urothelial CarcinomaCurrent Urology Reports, 2016